APA (7th ed.) Citation

Labrador, M., Cozzubbo, S., Porro, M., Cumerlato, M., Bandini, C., Mereu, E., . . . Piva, R. (2026). MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma. Cells (2073-4409), 15(9), 831. https://doi.org/10.3390/cells15090831

Chicago Style (17th ed.) Citation

Labrador, María, et al. "MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma." Cells (2073-4409) 15, no. 9 (2026): 831. https://doi.org/10.3390/cells15090831.

MLA (9th ed.) Citation

Labrador, María, et al. "MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma." Cells (2073-4409), vol. 15, no. 9, 2026, p. 831, https://doi.org/10.3390/cells15090831.